Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent provided
18 years or older
Relapsed/refractory AML: AML as defined by the WHO Classification persisting or recurring following one or more treatment courses except promyelocytic leukemia (APML)
You may not be if
Active extramedullary AML in testes or central nervous system (CNS)
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation (eg, sucrose, captisol, potassium, polysorbate 80, citrate, lysine)
Prior malignancy (other than in situ cancer) unless treated with curative intent and without evidence of disease for \> 1 years before screening
Clareo Health | A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
